CytomX Therapeutics is a clinical-stage biotechnology company developing antibody-based cancer therapies using its Probody platform. Probody candidates are designed to stay inactive in circulation and become activated primarily in the tumor microenvironment, aiming to widen the therapeutic window versus conventional antibodies. The pipeline centers on oncology targets pursued alone or with partners. Customers in the commercial sense are not yet the main story; value hinges on clinical progress and collaborations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 18.7 | — | -0.1 | — |
| Q3 2025 | 6 | — | -14.2 | — |
| Q4 2025 | 0.7 | — | -26.5 | — |
| Q1 2026 | 10.3 | — | -18.3 | — |
| Q2 2026 | 1.4 | -92.4% | -20.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Roma Green Finance Limited (ROMA), Weyco Group, Inc. (WEYS), ChoiceOne Financial Services, Inc. (COFS), Greenlight Capital Re, Ltd. (GLRE), Evotec SE (EVO), Mountain Lake Acquisition Corp. II (MLAA)